OBJECTIVE: We describe the use of fenoldopam to increase urine output in a pediatric patient with sepsis, heart failure, oliguria, and volume overload. DESIGN: Case report. SETTING: A tertiary pediatric intensive care unit. PATIENT: A 17-year-old male who was being treated for acute lymphoblastic leukemia and was admitted from outside the hospital to the pediatric intensive care unit, in septic shock, after a course of chemotherapy. INTERVENTIONS: A continuous fenoldopam infusion of 0.03 microg/kg/min was added to a regimen of multiple inotropic and vasopressor agents and a furosemide continuous infusion. MEASUREMENTS AND MAIN RESULTS: Urine output increased 586% 12 hrs after starting the fenoldopam infusion and 775% from baseline 24 hrs after starting the infusion. Diuretics were decreased while maintaining adequate urine output. No hypotension was noted. CONCLUSIONS: Fenoldopam increased urine output in a pediatric patient who was in septic shock and oliguria. The mechanism for this effect is unclear, and further trials are necessary to determine the role of fenoldopam in this patient population.
OBJECTIVE: We describe the use of fenoldopam to increase urine output in a pediatric patient with sepsis, heart failure, oliguria, and volume overload. DESIGN: Case report. SETTING: A tertiary pediatric intensive care unit. PATIENT: A 17-year-old male who was being treated for acute lymphoblastic leukemia and was admitted from outside the hospital to the pediatric intensive care unit, in septic shock, after a course of chemotherapy. INTERVENTIONS: A continuous fenoldopam infusion of 0.03 microg/kg/min was added to a regimen of multiple inotropic and vasopressor agents and a furosemide continuous infusion. MEASUREMENTS AND MAIN RESULTS: Urine output increased 586% 12 hrs after starting the fenoldopam infusion and 775% from baseline 24 hrs after starting the infusion. Diuretics were decreased while maintaining adequate urine output. No hypotension was noted. CONCLUSIONS:Fenoldopam increased urine output in a pediatric patient who was in septic shock and oliguria. The mechanism for this effect is unclear, and further trials are necessary to determine the role of fenoldopam in this patient population.
Authors: Chad A Knoderer; Jeffrey D Leiser; Corina Nailescu; Mark W Turrentine; Sharon P Andreoli Journal: Pediatr Nephrol Date: 2007-11-14 Impact factor: 3.714
Authors: Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg Journal: Crit Care Med Date: 2009-02 Impact factor: 7.598